Perhaps INMB wojld have benefitted from using the FDA’s open label adaptive ph 2 cross over trial like Anavex did. We are clearly on a firm foundation of efficacy because if the ph 2a as we near approval in the EU.
On a financing note, yes I also highly appreciate Dr. Missling’s clear savvy moves to minimally allow dilution to Anavex shareholders on the way to approval…..inhouse!
Management of INMB should be ashamed for securing a financing deal ahead of releasing bad news. Did the funding source know the data and shorted against the box? Smells very bad!
Market Data 
Markets 
AI
